Document is current
Any future updates will be listed below
-
Authors
Pretorius, Elizabeth
Kristan, Mojca
Bradley, John
da Silva, Eunice Teixeira
Hutchins, Harry
Barri, Fatucha
Cassama, Ansumane
Ceesay, Sainey
Ndiath, Mamadou Ousmane
Rodrigues, Amabelia
Logan, James G.
Last, Anna
Jones, Robert T.
-
Funding
Funding for this research was provided by:
Joint Global Health Trials award (MR/S005013/1)
Joint Global Health Trials award (MR/S005013/1)
Joint Global Health Trials award (MR/S005013/1)
Joint Global Health Trials award (MR/S005013/1)
Joint Global Health Trials award (MR/S005013/1)
Joint Global Health Trials award (MR/S005013/1)
Joint Global Health Trials award (MR/S005013/1)
Joint Global Health Trials award (MR/S005013/1)
- License Information
-
More Information
Article History
Received: 9 June 2023
Accepted: 4 July 2023
First Online: 15 July 2023
Declarations
:
: This study is nested within a larger cluster-randomised placebo-controlled trial investigating the use of adjunctive ivermectin mass drug administration for malaria control on the Bijagós Archipelago of Guinea-Bissau (MATAMAL). Ethics approval was given by LSHTM Research Ethics Committee (UK) (19156) and Comité Nacional de Ética em Pesquisa na Saúde (CNES; Guinea-Bissau) (084/CNES/INASA/2020).
: Not applicable.
: The authors declare no competing interests.
